The Latest Cardiac and Vascular News
— Late-Breaking Clinical Data Presented at the Technology and Heart Failure Therapeutics (THT) Annual Meeting Demonstrates Safety and Efficacy of the Reprieve System Compared to Optimal Diuretic Therapy to Manage Fluid Volume Overload — — Company Plans Initiation of Randomized Pivotal Trial in the First Half of 2025 to Support Premarket Approval Submission — February 11, […]
December 16, 2024 08:00 AM Eastern Standard Time MILFORD, Mass. & FRANKFURT, Germany–(BUSINESS WIRE)–Reprieve Cardiovascular, Inc., a development-stage company focused on advancing acute decompensated heart failure (ADHF) treatment, today announced the first-in-human results of the Reprieve System at the CSI Focus D-HF (Device therapies in heart failure) conference in Frankfurt, Germany. Results of the study […]
MILFORD, Mass.–(BUSINESS WIRE)–Reprieve Cardiovascular, Inc., a development-stage company pioneering an intelligent automated diuretic and fluid management approach for acute decompensated heart failure (ADHF) treatment, today announced the completion of enrollment in the “Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve System (“FASTR”)” trial. “For decades, managing fluid removal in patients with ADHF has presented a significant […]
MILFORD, Mass.–(BUSINESS WIRE)–Reprieve Cardiovascular, Inc. (‘Reprieve’), a development stage company focused on pioneering an intelligent approach to acute decompensated heart failure (ADHF) treatment, today highlighted the publication of TREAT-AHF study results in JACC: Heart Failure. “The data highlights the opportunities to improve care, but it will take a sustained partnership among hospital systems, physicians, nurses, and industry […]
MILFORD, Mass.–(BUSINESS WIRE)–Reprieve Cardiovascular, Inc., a development stage company focused on pioneering an intelligent automated diuretic and fluid management approach for acute decompensated heart failure (ADHF) treatment, today announced it has raised a total of $42 million in series A financing. The total round was co-led by Lightstone Ventures and Sante Ventures and joined by […]
Personalized Volume Management System : 2nd generation automated fluid management technology MILFORD, Mass., Dec. 13, 2019 /PRNewswire/ — Reprieve Cardiovascular®, a pioneering medical device company focused on improving outcomes for patients suffering from acute decompensated heart failure (ADHF), today announced the results of the first-in-human clinical trial with the company’s second generation device, the Personalized Volume Management System […]
MILFORD, Mass.–(BUSINESS WIRE)–Reprieve Cardiovascular™, a pioneering medical device company focused on improving outcomes for patients suffering from Acute Decompensated Heart Failure (ADHF), today announced the results of two non-randomized, prospective clinical trials in patients hospitalized with Acute Heart Failure (AHF). The two studies demonstrate that using Reprieve-Guided Diuretic Therapy, the first fully automated fluid management […]
MILFORD, Massachusetts – ( BUSINESS WIRE ) – Reprieve Cardiovascular ™, a pioneering medical device company focused on improving the treatment of patients with acute decompensated heart failure (ADHF), will soon be at various well-known sites Conferences for Heart Failure represented. Reprieve-guided diuretic therapy will be the subject of the two presentations at ICI 2018, the International Congress […]
